Drug firm Zydus Cadila on Wednesday said it has launched its affordable oral anti-diabetic Vinglyn brand tablets available in two formulations in India.
As the product patent on popular diabetes drug Vildagliptin has expired in India on December 9, some domestic drug firms have launched the generic versions of the drug in the country that are much cheaper than the patented medicine.
“Priced at just Rs 4.95 per tablet, which is almost 1/6th the price at which the patented Vildagliptin was initially launched in India, Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India,” Zydus Cadila said in a statement.
Vinglyn and Vinglyn M will be marketed by Zydus Healthcare Ltd, it added.
Zydus Cadila Managing Director Sharvil Patel said, “Fortifying our fight against diabetes, our aim is to make therapies affordable and accessible to patients from across sections of society.”
With Vinglyn, Zydus Cadila believes that it has once again been able to offer this. The access to one of the most affordable gliptin therapies will help a large number of patients suffering from type-2 diabetes, in India, he added.
